Prosecution Insights
Last updated: April 19, 2026

Atriva Therapeutics GmbH

2 pending office actions

Portfolio Summary

2
Total Pending OAs
1
Final Rejections
1
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18443904 MEK-INHIBITOR FOR THE TREATMENT OF VIRAL AND BACTERIAL INFECTIONS WILSON, JERICA KATLYNN 1621 Non-Final OA Feb 16, 2024
17999185 MEK-INHIBITORS FOR THE TREATMENT OR PREVENTION OF CORONAVIRUS INFECTIONS AND/OR COVID-19 CYTOKINE STORM NESTOR, DONNA MICHELLE 1627 Final Rejection Nov 17, 2022

Managing Atriva Therapeutics GmbH's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month